Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (CTXR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CTXR · as of Sep 30, 2025
Ownership Breakdown
37
Institutional Holders
▲ 2 vs Q2
$773,221
Total Inst. Value
▼ $703,846 vs Q2
11.17M
Shares Outstanding
freeFloat 94.26%
624,408
13F Shares Held
▼ 304,358 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CTXR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC pharmaceutical preparations | 166.4K | 1.51% | 1.51% | $206.32M | Nov 7, 2025 | ▲ 86.3K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 119.8K | 1.09% | 1.09% | $148.54M | Nov 12, 2025 | ▲ 43.7K |
CITADEL ADVISORS LLC pharmaceutical preparations | 92.3K | 83.86% | 83.86% | $114.45M | Nov 14, 2025 | ▲ 56.5K |
BLACKROCK, INC. pharmaceutical preparations | 69.9K | 63.46% | 63.46% | $86.61M | Nov 12, 2025 | — held |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 48.2K | 43.78% | 43.78% | $59.75M | Nov 14, 2025 | ▲ 34.0K |
NORTHERN TRUST CORP pharmaceutical preparations | 27.0K | 24.55% | 24.55% | $33.51M | Nov 14, 2025 | ▲ 12.7K |
UBS GROUP AG pharmaceutical preparations | 25.9K | 23.54% | 23.54% | $32.13M | Nov 13, 2025 | ▼ 167.0K |
NEWEDGE ADVISORS, LLC pharmaceutical preparations | 25.4K | 23.08% | 23.08% | $31.50M | Nov 17, 2025 | ▲ 400 |
STATE STREET CORP pharmaceutical preparations | 23.3K | 21.14% | 21.14% | $28.86M | Nov 14, 2025 | — held |
SUSQUEHANNA INTERNATIONAL GROUP, LLP pharmaceutical preparations | 22.8K | 20.71% | 20.71% | $28.27M | Nov 14, 2025 | ▲ 9.5K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
13
Increased
+262.0K shares6
New Positions
first time holders5
Decreased
−359.7K shares6
Sold Out
fully exitedNet shares change (top 50)
97.7K
+262.0K / −359.7K
Net new holders
+8
6 new / 6 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CTXR insider trading · insider activity
Source: SEC Form 4
4
Buy transactions
4
Sell transactions
1.00
Buy/Sell ratio
$7M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Mazur Leonard L Chief Executive Officer | Aug 8, 2025 | Award | 125,490 | $28.75 | $3.61M | 125.5K | Form 4 ↗ |
Mazur Leonard L Chief Executive Officer | Aug 8, 2025 | Award | 89,388 | $19.25 | $1.72M | 89.4K | Form 4 ↗ |
Mazur Leonard L Chief Executive Officer | Aug 8, 2025 | D-Return | 125,490 | $28.75 | $3.61M | 0 | Form 4 ↗ |
Mazur Leonard L Chief Executive Officer | Aug 8, 2025 | D-Return | 89,388 | $19.25 | $1.72M | 0 | Form 4 ↗ |
HOLUBIAK MYRON Z Vice Chairman | Aug 8, 2025 | Award | 31,373 | $28.75 | $902.0K | 31.4K | Form 4 ↗ |
HOLUBIAK MYRON Z Vice Chairman | Aug 8, 2025 | Award | 22,344 | $19.25 | $430.1K | 22.3K | Form 4 ↗ |
HOLUBIAK MYRON Z Vice Chairman | Aug 8, 2025 | D-Return | 22,344 | $19.25 | $430.1K | 0 | Form 4 ↗ |
HOLUBIAK MYRON Z Vice Chairman | Aug 8, 2025 | D-Return | 31,373 | $28.75 | $902.0K | 0 | Form 4 ↗ |
Webb Carol director | Nov 7, 2024 | Award | 125,000 | $0.38 | $47.5K | 125.0K | Form 4 ↗ |
Smith Robert Joseph director | Nov 7, 2024 | Award | 125,000 | $0.38 | $47.5K | 125.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Citius Pharmaceuticals, Inc. (CTXR) is primarily owned by institutional investors, who hold approximately 5.6% of total shares outstanding. Company insiders own approximately 5.74%, while retail and public investors account for the remaining 88.68%.
The largest institutional shareholder of Citius Pharmaceuticals, Inc. is VANGUARD GROUP INC, holding approximately 166,390 shares — equal to 1.51% of outstanding shares — as of September 30, 2025.
A total of 37 institutional investors currently hold CTXR stock, with a combined institutional value of approximately $773,221 as of the most recent 13F filing period.
Frequently asked questions
CTXR ownershipCitius Pharmaceuticals, Inc. (CTXR) is primarily owned by institutional investors, who hold approximately 5.6% of shares. The largest shareholder is VANGUARD GROUP INC with a 1.51% stake. Company insiders hold 5.74%. Data sourced from SEC Form 13F as of September 30, 2025.